19 November 2012
Nephrotic syndrome associated with gemcitabine use in a patient with ovarian cancer
Alper Ata, Iclal Gürses, Ahmet Kıykım, Ali ArıcanDOI: 10.12659/AJCR.883583
Am J Case Rep 2012; 13:268-270
Abstract
Background: Here we present a patient who developed nephrotic syndrome associated with gemcitabine use.
Case Report: Gemcitabine therapy was initiated following tumor recurrence in a patient with ovarian cancer, who was previously treated twice with carboplatin and paclitaxel. Radiological findings waned and tumor marker concentrations decreased after gemcitabine treatment. However, edema and ascites development was observed on the fifth treatment cycle. Laboratory results revealed increased blood urea nitrogen and creatinine levels, decreased serum albumin concentrations, and increased 24-hour urinary protein excretion. Renal biopsy findings were compatible with membranous glomerulonephritis. Gemcitabine administration was stopped and the cyclophosphamide and steroid therapy were initiated. The symptoms and findings disappeared after the cessation of gemcitabine and immunosuppressive treatment.
Conclusions: Gemcitabine treatment may be associated with proteinuria to the extent of nephrotic syndrome.
Keywords: Gemcitabine, nephrotic syndrome, Ovarian cancer
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945795
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946588
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946011
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945910
Most Viewed Current Articles
21 Jun 2024 : Case report
88,761
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,081
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,336
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,657
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030